Diabetes Therapy最新文献

{"title":"Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study","authors":"B. Bonora, R. Cappellari, M. Grasso, M. Mazzucato, Marianna D’Anna, A. Avogaro, G. Fadini","doi":"10.1007/s13300-022-01273-5","DOIUrl":"https://doi.org/10.1007/s13300-022-01273-5","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1327 - 1337"},"PeriodicalIF":3.8,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43116932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies","authors":"M. Hassanein, M. Akbar, M. Al-Shamiri, A. Amir, A. Amod, R. Chudleigh, T. Elhadd, H. Heshmat, M. Jibani, Yousef Al Saleh","doi":"10.1007/s13300-022-01282-4","DOIUrl":"https://doi.org/10.1007/s13300-022-01282-4","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1253 - 1280"},"PeriodicalIF":3.8,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47937109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise Intervention as a Therapy in Patients with Diabetes Mellitus and Sarcopenia: A Meta-Analysis","authors":"Siyao Gao, Ling Yu, Guozhong Yi, Tong Li, Zhenyin Chen, Jiawang Ding","doi":"10.1007/s13300-022-01275-3","DOIUrl":"https://doi.org/10.1007/s13300-022-01275-3","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1311 - 1325"},"PeriodicalIF":3.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42267964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin","authors":"S. Aravind, K. Singh, Liliia Mogylnytska, A. Zalevskaya, B. Matyjaszek-Matuszek, K. Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, D. Kramer, Bhaswati Mukherjee","doi":"10.1007/s13300-022-01279-z","DOIUrl":"https://doi.org/10.1007/s13300-022-01279-z","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1299 - 1310"},"PeriodicalIF":3.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49663234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.","authors":"Rory J McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Amar Puttanna","doi":"10.1007/s13300-022-01267-3","DOIUrl":"10.1007/s13300-022-01267-3","url":null,"abstract":"<p><strong>Introduction: </strong>iGlarLixi is indicated as an adjunct to diet and exercise in addition to metformin (with or without sodium-glucose cotransporter-2 inhibitors) to improve glycemic control in adults with insufficiently controlled type 2 diabetes (T2D). A cost-effectiveness analysis was conducted to compare iGlarLixi with premix biphasic insulin aspart 30 (BIAsp 30) in people with T2D suboptimally controlled with basal insulin (BI).</p><p><strong>Methods: </strong>The IQVIA CORE Diabetes Model was used to estimate lifetime costs and outcomes for people with T2D from a UK health care perspective at a willingness-to-pay threshold of £20,000. Initial clinical data were based on the phase 3 randomized, open-label, active-controlled SoliMix clinical trial which compared the efficacy and safety of once-daily iGlarLixi with that of twice-daily BIAsp 30. Costs associated with management and complications and utilities values were derived from published sources. Lifetime costs (in £GBP) and quality-adjusted life-years (QALYs) were predicted; extensive scenario and sensitivity analyses were conducted.</p><p><strong>Results: </strong>Estimated QALYs gained were slightly higher with iGlarLixi (8.9 vs. 8.8) compared with premix BIAsp 30, at a higher cost (£23,204 vs. £21,961). The base case incremental cost-effectiveness ratio (ICER) per QALY was £13,598. Treatment acquisition was the main driver of cost differences (iGlarLixi, £11,750; premix BIAsp 30, £10,395). Costs associated with management and complications were generally similar between comparators.</p><p><strong>Conclusion: </strong>iGlarLixi provides improved QALY outcomes at an acceptable cost compared with premix BIAsp 30, with an ICER below the threshold generally considered acceptable by UK authorities. In people with T2D, iGlarLixi is a simple, cost-effective option for advancing therapy of BI, with fewer daily injections than premix BIAsp 30.</p>","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1203-1214"},"PeriodicalIF":2.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47272025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)","authors":"Lixin Guo, Li Li, Qiurong Yu, Na Wang, Jun Chen, Zhiquan Wang, Yuchen Ding","doi":"10.1007/s13300-022-01268-2","DOIUrl":"https://doi.org/10.1007/s13300-022-01268-2","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1231 - 1244"},"PeriodicalIF":3.8,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44506315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers","authors":"Y. Schnaars, Sumedh Gaikwad, U. Gottwald-Hostalek, Ulrike Klingberg, Harikiran Chary Vadla, V. Prathap","doi":"10.1007/s13300-022-01269-1","DOIUrl":"https://doi.org/10.1007/s13300-022-01269-1","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1215 - 1229"},"PeriodicalIF":3.8,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43474871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study","authors":"G. Galstyan, A. Tirosh, H. Vargas-Uricoechea, M. A. Mabunay, M. Coudert, M. Naqvi, V. Pilorget, N. Khan","doi":"10.1007/s13300-022-01266-4","DOIUrl":"https://doi.org/10.1007/s13300-022-01266-4","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1187 - 1202"},"PeriodicalIF":3.8,"publicationDate":"2022-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44636293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Semaglutide: Dosage in Special Situations","authors":"S. Kalra, N. Kapoor","doi":"10.1007/s13300-022-01265-5","DOIUrl":"https://doi.org/10.1007/s13300-022-01265-5","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1133 - 1137"},"PeriodicalIF":3.8,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49605005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden.","authors":"J Jendle, M I Buompensiere, A L Holm, S de Portu, S J P Malkin, O Cohen","doi":"10.1007/s13300-022-01252-w","DOIUrl":"10.1007/s13300-022-01252-w","url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"13 1","pages":"1125-1129"},"PeriodicalIF":2.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44478283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}